These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35830231)

  • 41. Antisense oligonucleotide treatment produces a type I interferon response that protects against diet-induced obesity.
    McCabe KM; Hsieh J; Thomas DG; Molusky MM; Tascau L; Feranil JB; Qiang L; Ferrante AW; Tall AR
    Mol Metab; 2020 Apr; 34():146-156. PubMed ID: 32180554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel and translational role for autophagy in antisense oligonucleotide trafficking and activity.
    Ochaba J; Powers AF; Tremble KA; Greenlee S; Post NM; Matson JE; MacLeod AR; Guo S; Aghajan M
    Nucleic Acids Res; 2019 Dec; 47(21):11284-11303. PubMed ID: 31612951
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Solid-phase synthesis of 5'-triantennary N-acetylgalactosamine conjugated antisense oligonucleotides using phosphoramidite chemistry.
    Prakash TP; Brad Wan W; Low A; Yu J; Chappell AE; Gaus H; Kinberger GA; Østergaard ME; Migawa MT; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4127-30. PubMed ID: 26299345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficient Synthesis and Biological Evaluation of 5'-GalNAc Conjugated Antisense Oligonucleotides.
    Østergaard ME; Yu J; Kinberger GA; Wan WB; Migawa MT; Vasquez G; Schmidt K; Gaus HJ; Murray HM; Low A; Swayze EE; Prakash TP; Seth PP
    Bioconjug Chem; 2015 Aug; 26(8):1451-5. PubMed ID: 26011654
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro metabolism of 2'-ribose unmodified and modified phosphorothioate oligonucleotide therapeutics using liquid chromatography mass spectrometry.
    Kim J; El Zahar NM; Bartlett MG
    Biomed Chromatogr; 2020 Jul; 34(7):e4839. PubMed ID: 32246854
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Endosomal Escape of Antisense Oligonucleotides Internalized by Stabilin Receptors Is Regulated by Rab5C and EEA1 During Endosomal Maturation.
    Miller CM; Wan WB; Seth PP; Harris EN
    Nucleic Acid Ther; 2018 Apr; 28(2):86-96. PubMed ID: 29437530
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Application of a Quality-By-Design Approach to Optimise Lipid-Polymer Hybrid Nanoparticles Loaded with a Splice-Correction Antisense Oligonucleotide: Maximising Loading and Intracellular Delivery.
    Thanki K; Papai S; Lokras A; Rose F; Falkenberg E; Franzyk H; Foged C
    Pharm Res; 2019 Jan; 36(3):37. PubMed ID: 30623253
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quantification of Antisense Oligonucleotides by Splint Ligation and Quantitative Polymerase Chain Reaction.
    Shin M; Meda Krishnamurthy P; Devi G; Watts JK
    Nucleic Acid Ther; 2022 Feb; 32(1):66-73. PubMed ID: 34928745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection.
    Byrnes AE; Dominguez SL; Yen CW; Laufer BI; Foreman O; Reichelt M; Lin H; Sagolla M; Hötzel K; Ngu H; Soendergaard C; Estevez A; Lin HC; Goyon A; Bian J; Lin J; Hinz FI; Friedman BA; Easton A; Hoogenraad CC
    Mol Ther Nucleic Acids; 2023 Jun; 32():773-793. PubMed ID: 37346977
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells.
    Wang S; Allen N; Prakash TP; Liang XH; Crooke ST
    Nucleic Acid Ther; 2019 Oct; 29(5):245-255. PubMed ID: 31158063
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.
    Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM
    Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics.
    Ramasamy T; Ruttala HB; Munusamy S; Chakraborty N; Kim JO
    J Control Release; 2022 Dec; 352():861-878. PubMed ID: 36397636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle.
    Prakash TP; Mullick AE; Lee RG; Yu J; Yeh ST; Low A; Chappell AE; Østergaard ME; Murray S; Gaus HJ; Swayze EE; Seth PP
    Nucleic Acids Res; 2019 Jul; 47(12):6029-6044. PubMed ID: 31127296
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Safety, Tissue Distribution, and Metabolism of LNA-Containing Antisense Oligonucleotides in Rats.
    Romero-Palomo F; Festag M; Lenz B; Schadt S; Brink A; Kipar A; Steinhuber B; Husser C; Koller E; Sewing S; Tessier Y; Dzygiel P; Fischer G; Winter M; Hetzel U; Mihatsch MJ; Braendli-Baiocco A
    Toxicol Pathol; 2021 Aug; 49(6):1174-1192. PubMed ID: 34060347
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overcoming the challenges of tissue delivery for oligonucleotide therapeutics.
    Gökirmak T; Nikan M; Wiechmann S; Prakash TP; Tanowitz M; Seth PP
    Trends Pharmacol Sci; 2021 Jul; 42(7):588-604. PubMed ID: 34020790
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
    Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
    Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduction of liver tumor necrosis factor-alpha expression by targeting delivery of antisense oligonucleotides into Kupffer cells protects rats from fulminant hepatitis.
    Dong L; Zuo L; Xia S; Gao S; Zhang C; Chen J; Zhang J
    J Gene Med; 2009 Mar; 11(3):229-39. PubMed ID: 19189285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes.
    Liang XH; Sun H; Hsu CW; Nichols JG; Vickers TA; De Hoyos CL; Crooke ST
    Nucleic Acids Res; 2020 Feb; 48(3):1372-1391. PubMed ID: 31840180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.